Penumbra (PEN) reported second-quarter 2026 revenue of $390.0 million, up 14.9% from the prior-year period. Net income was $34.8 million, compared with $45.3 million a year earlier.
The company said it will not provide full-year 2026 financial guidance or host a conference call because of its pending acquisition by Boston Scientific Corporation.
- Second-quarter revenue was $390.0 million, up 14.9% year over year.
- Global thrombectomy revenue was $259.0 million, up 12.5% from the second quarter of 2025.
- Global embolization and access revenue was $131.1 million, up 20.0% year over year.
- Gross profit margin was 67.9%, up 1.9 percentage points from the prior-year quarter.
- Total operating expenses were $223.9 million, including $6.9 million of acquisition-related expenses.
- Net income was $34.8 million, and diluted earnings per share were $0.88.
$PEN Insider Trading Activity
$PEN insiders have traded $PEN stock on the open market 2 times in the past 6 months. Of those trades, 0 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $PEN stock by insiders over the last 6 months:
- MAGGIE YUEN (Chief Financial Officer) sold 2,432 shares for an estimated $832,473
- HARPREET GREWAL sold 100 shares for an estimated $32,822
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$PEN Hedge Fund Activity
We have seen 235 institutional investors add shares of $PEN stock to their portfolio, and 221 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FMR LLC removed 4,635,835 shares (-90.3%) from their portfolio in Q1 2026, for an estimated $1,522,269,138
- HBK INVESTMENTS L P added 1,634,261 shares (+inf%) to their portfolio in Q1 2026, for an estimated $536,642,284
- PRICE T ROWE ASSOCIATES INC /MD/ removed 1,602,174 shares (-97.5%) from their portfolio in Q1 2026, for an estimated $526,105,876
- RTW INVESTMENTS, LP removed 866,499 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $284,532,276
- CITADEL ADVISORS LLC removed 787,550 shares (-79.5%) from their portfolio in Q1 2026, for an estimated $258,607,793
- BALYASNY ASSET MANAGEMENT L.P. added 600,185 shares (+370.7%) to their portfolio in Q1 2026, for an estimated $197,082,748
- ARTISAN PARTNERS LIMITED PARTNERSHIP removed 594,112 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $195,088,557
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
